Compare
Novavax Inc vs Halozyme Therapeutics, Inc. vs BioCryst Pharmaceuticals Inc vs Repligen Corp
| Latest fiscal year | Novavax Inc NVAX | Halozyme Therapeutics, Inc. HALO | BioCryst Pharmaceuticals Inc BCRX | Repligen Corp RGEN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.12B | $1.40B | $874.84M | $738.26M |
| Revenue growth (YoY) | +64.7% | +37.6% | +94.1% | +16.4% |
| Gross margin | 93.5% (computed) | 83.6% (computed) | n/a | 52.3% (computed) |
| Operating margin | 40.3% | 33.6% | 39.0% | 7.5% |
| Net margin | 39.2% | 22.7% | 30.2% | 6.6% |
| Net income | $440.30M | $316.89M | $263.86M | $48.89M |
| EPS (Diluted) | $2.58 | $2.56 | $1.21 | $0.86 |
| Operating cash flow | -$244.63M | $651.56M | $347.37M | $117.42M |
| Free cash flow | n/a | $644.59M | $344.90M | $93.90M |
| Cash & equivalents | $240.63M | $133.82M | $89.74M | $566.02M |
| Total assets | $1.18B | $2.53B | $514.16M | $2.95B |
| Total liabilities | $1.30B | $2.48B | $633.31M | $843.57M |
| Shareholders' equity | -$127.75M | $48.81M | -$119.15M | $2.11B |
| Return on year-end equity | n/a | 649.2% | n/a | 2.3% |
| Shares outstanding | 162.58M | 117.78M | 213.06M | 56.33M |
Revenue, most recent five fiscal years
| Fiscal year | Novavax Inc | Halozyme Therapeutics, Inc. | BioCryst Pharmaceuticals Inc | Repligen Corp |
|---|---|---|---|---|
| Latest | $1.12B Ended 2025-12-31 | $1.40B Ended 2025-12-31 | $874.84M Ended 2025-12-31 | $738.26M Ended 2025-12-31 |
| 1 year earlier | $682.16M Ended 2024-12-31 | $1.02B Ended 2024-12-31 | $450.71M Ended 2024-12-31 | $634.44M Ended 2024-12-31 |
| 2 years earlier | $983.71M Ended 2023-12-31 | $829.25M Ended 2023-12-31 | $331.41M Ended 2023-12-31 | $632.36M Ended 2023-12-31 |
| 3 years earlier | $1.98B Ended 2022-12-31 | $660.12M Ended 2022-12-31 | $270.83M Ended 2022-12-31 | $801.54M Ended 2022-12-31 |
| 4 years earlier | $1.15B Ended 2021-12-31 | $443.31M Ended 2021-12-31 | $157.17M Ended 2021-12-31 | $670.53M Ended 2021-12-31 |